CSL Limited Annual Report 2021/22 55 Board of Directors Brian McNamee AO MBBS, FTSE Chair and Independent Non-Executive Director Director of CSL Limited since February 2018 and Chair fromOctober 2018. Dr McNamee has deep executive experience in the biopharmaceutical industry, with a focus on strategy and creating long-term shareholder value. Dr McNamee was the Chief Executive Officer and Managing Director of CSL from 1990 until 2013. Since leaving his executive role at CSL, Dr McNamee has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued a number of private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government’s Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. Other directorships and offices (current and recent): – Chair of Geoff Ogilvy Foundation (since May 2021); and – Former Chair of GenesisCare Limited (from July 2019 to June 2022). Board Committee memberships: – Member of the Innovation and Development Committee; – Member of the Corporate Governance and Nomination Committee; and – Member of the Securities and Market Disclosure Committee. Paul Perreault BA (Psychology) Non-independent Executive Director Director of CSL Limited since February 2013, and appointed Chief Executive Officer and Managing Director in July 2013. Mr Perreault has more than 37 years of experience across both the global biotech and pharmaceutical industries. He was appointed Chief Executive Officer and Managing Director of CSL Limited in July 2013, and was appointed to the CSL Board of Directors the same year. Since then, CSL has grown to become the third largest biotech company in the world, with more than 30,000 employees bringing lifesaving medicines to people in more than 100 countries. Mr Perreault, who previously served as CSL Behring’s president, joined CSL in 2004 with the acquisition of Aventis Behring. Prior to CSL, he spent more than 15 years in key senior roles at Wyeth-Ayerst Laboratories, now part of Pfizer. Mr Perreault holds a bachelor’s degree in psychology from the University of Central Florida and completed advanced business management training at the Kellogg and Wharton schools of business. Other directorships and offices (current and recent): – Director of the US Pharmaceutical Research and Manufacturers of America Association (PhRMA) (since December 2020). Board Committee memberships: – Member of the Innovation and Development Committee; and – Member of the Securities and Market Disclosure Committee. Bruce Brook BCom, BAcc, FCA, MAICD Independent Non-Executive Director Director of CSL Limited since August 2011. Mr Brook has an extensive breadth of executive experience in diverse industries, including mining, finance, manufacturing and chemicals. In particular, Mr Brook has valuable insight and experience in relation to risk, capital discipline, change management, corporate culture and creating shareholder value. Mr Brook was chief financial officer of WMC Resources Limited from 2002 to 2005. He also held key executive roles including deputy chief finance officer of ANZ Banking Group Limited, group chief accountant of Pacific Dunlop Limited and general manager, Group Accounting positions at CRA Limited and Pasminco Limited. Other directorships and offices (current and recent): – Director of Djerriwarrh Investments Limited (since August 2021); – Director of Guide Dogs Victoria (since November 2018); – Director of Incitec Pivot Limited (since December 2018); and – Director of Newmont Corporation (since October 2011). Board Committee memberships: – Chair of the Audit and Risk Management Committee; and – Member of the Corporate Governance and Nomination Committee.
RkJQdWJsaXNoZXIy MjE2NDg3